Connor Lynch

PGY-5 Resident @UChicagoRadOnc. I endorse RT but RTs are not endorsements.

[Connor Lynch @ConnorLynchMD]

Thanks to @ajuloorimd, @mkorps42, @RohanKatipally, @SeanPitroda, @Docace911, @ChristineBestv1, @jasonlukemd, and @JPatelMD for contributions to this work!

[Connor Lynch @ConnorLynchMD]

Online now: our report in EJC compiles toxicity data from 213 pts across 3 multi-site SBRT + immune checkpoint inhibitor trials at UChicago to characterize the toxicity profile of combined modality treatment: https://t.co/n6o113ybzu

[Connor Lynch @ConnorLynchMD]

We found rates of toxicity were similar to those seen in major trials of ICI alone, suggesting that SBRT adds minimal toxicity (consistent with low rates of SBRT tox in SABR-5 and recently OligoCare). Critically, standard SBRT constraints were used with priority on OAR sparing.

[Connor Lynch @ConnorLynchMD]

@NiuSanford @SeanPitroda Thanks for reading!

[The Lancet Oncology @TheLancetOncol]

New Review in the August issue: Radiotherapy, immunity, and immune checkpoint inhibitors

#radiotherapy #ImmuneCheckpointInhibitors
https://t.co/4wVAClMfPD

[Connor Lynch @ConnorLynchMD]

@SeanPitroda @rweichselbaum @TheLancetOncol @Ludwig_Cancer @UChicago @UCCancerCenter @UChicagoRadonc Thank you! Also a great team effort!

[Connor Lynch @ConnorLynchMD]

Considering negative trials of radiation and immunotherapy in light of available preclinical and translational data. Our review of this rapidly evolving field: https://t.co/9Ym4qazNkX

[Connor Lynch @ConnorLynchMD]

@rweichselbaum @SeanPitroda @MuzamilArshad18 @RohanKatipally @UCCancerCenter Thank you! It was great working with you and the rest of the team on this

[Connor Lynch @ConnorLynchMD]

Could we hold off on checkpoint inhibitors in patients with low-volume metastatic disease and treat with local therapy instead? Our editorial exploring this idea: https://t.co/nR8582LmMZ (thanks to @rweichselbaum @MuzamilArshad18 @RohanKatipally @SeanPitroda)

[Connor Lynch @ConnorLynchMD]

More interesting findings from UChicago Chem and Rad Onc (@rweichselbaum lab) on STING activation and the tumor microenvironment https://t.co/54g8oHJLCq

[Connor Lynch @ConnorLynchMD]

@UChicagoRadonc Thanks!

[Connor Lynch @ConnorLynchMD]

@ajuloorimd @UCCancerCenter Thanks for the shoutout! One of the great things about training @UChicagoRadonc is working with cool data like this. Looking at our SBRT/ICI trial data we realized we had a kind of natural experiment going on (ICI w/ or w/o liver met SBRT).

[Connor Lynch @ConnorLynchMD]

@ajuloorimd @UCCancerCenter @UChicagoRadonc Reassuringly we found that overall combined modality treatment is, as @Docace911 always says, SAFE. Given that our liver constraints were easily met, there is likely room to dose-escalate for these tougher-to-control liver mets.

[Connor Lynch @ConnorLynchMD]

@ajuloorimd @UCCancerCenter Thanks for the shoutout! One of the great things about training @UChicagoRadonc is working with cool data like this. Looking at our SBRT/ICI trial data we realized we had a kind of natural experiment going on (ICI w/ or w/o liver met SBRT).